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Rapid communications
Mu M p s in ir e l a n d, 2004-2008
S Gee1, D O’Flanagan (darina.oflanagan@hse.ie)1, M Fitzgerald1, S Cotter1
1. Health Protection Surveillance Centre, Dublin, Ireland 
Following a national mumps outbreak that began in November 
2004 and continued into 2005, the number of mumps notifications 
in Ireland waned in the latter half of 2006 and during 2007 (Figure 
1). However, mumps notifications have started to increase again 
in 2008 (Figure 1). The number of mumps notifications annually 
between 1988 and 2008 and the number of confirmed mumps 
notifications by year from 2004 to 2008 are shown in Figure 2. In 
total, there were 420 mumps notifications in 2004, 1,079 in 2005, 
427 in 2006, 150 in 2007 and to date there are 153 notifications 
in 2008 (Figure 2). In contrast, there were 40 mumps notifications 
in 2003 (Figure 2).
The highest number of notifications and the highest incidence 
rates, from the start of the outbreak in Week 44 of 2004 to Week 
16 of 2008, were in the age groups 15-19 years and 20-24 years 
(Figures 3 and 4). The setting in which the cases had most likely 
acquired mumps was reported for 25 percent of the notifications 
(n=535/2156) since the start of the outbreak; for the majority 
of these, college/university (48 percent) or secondary school (12 
percent) were reported as the locations the infection was most likely 
to have been acquired. 
Vaccination status was only reported for 35 percent (n=753/2156) 
of notifications since November 2004. Where vaccination status 
was reported, 35 percent of the cases were unvaccinated, 36 
percent had received one dose of the combined measles-mumps-
rubella vaccine (MMR), 28 percent had received two doses and one 
percent had received at least one dose (but it was unclear if they 
had also received a second dose). Reported vaccination status was 
obtained through a number of sources, such as local immunisation 
databases, general practitioner’s records and case/parental records 
or recall. Due to recall bias by cases/parents, there may therefore 
be some inaccuracies in the vaccination status figures reported 
above.
Eighty-four cases were hospitalised, representing 10 percent 
(n=84/855) of all cases with known hospitalisation status. Reported 
complications of mumps include orchitis (19 percent, n=86/442), 
deafness (1.6 percent, n=11/707), meningitis (1.5 percent, 
n=11/718), pancreatitis (1 percent, n=6/629), mastitis (0.6 
percent, n=4/644) and encephalitis (0.3 percent, n=2/714).
Notification data 2008
In contrast to the 153 mumps notifications for Weeks 1-16 
2008, there were 34 mumps notifications during the same period in 
2007 and 150 mumps notifications for the whole of 2007 (Figures 
1 and 2). To date in 2008, 87 of the 153 notifications are classified 
as laboratory-confirmed, nine as probable, 43 as possible, while 
14 have no case classification specified. 
The highest number of notifications in 2008 are in the age 
groups 15-19 years (n=34), 20-24 years (n=26) and 25-34 years 
(n=33), while the highest incidence rates are in those 15-19 
years (Figures 5 and 6). The setting in which the case most likely 
acquired mumps was reported for 53 notifications; school/college/
university (34 percent), social setting (23 percent) and family/
household (23 percent) were the most frequently reported as the 
place the infection was most likely acquired. Fifty-nine percent of 
cases are male and 40 percent are female; sex was not reported 
for 1 percent. 
Of the 153 notifications, the vaccination status was unknown 
or unreported for 50 percent; 20 percent were unvaccinated; 17 
percent had one dose of MMR and 13 percent had two doses of 
MMR. 
Four cases have been hospitalised in 2008, representing five 
percent (n=4/79) of all cases with known hospitalisation status. 
Reported complications of mumps included orchitis (30 percent, 
n=16/54), deafness (1 percent, n=1/79) and pancreatitis (1 
percent, n=1/78). No cases of meningitis (n=0/78), encephalitis 
(n=0/79) or mastitis (n=0/79) due to mumps were reported.
Six outbreaks of mumps have been notified to date for 2008. One 
outbreak was notified in Week 15 in the Health Service Executive 
(HSE) Mid Western Area (community outbreak with 15 cases). Two 
outbreaks were notified in Week 14; one was notified in the HSE 
South Eastern Area (college outbreak with seven cases) and one in 
the HSE Eastern Region (school outbreak with seven cases). One 
outbreak was notified in Week 12 in the HSE North Western Area 
(private household outbreak with three cases), one in Week 10 in 
the HSE Southern Area (school outbreak with two cases) and one 
in Week 7 in the HSE North Western Area (private household with 
two cases).
Please note that the 2007 and 2008 notification data are provisional.
MMR uptake in Ireland
Mumps vaccine in Ireland is available as part of the MMR 
vaccine. Vaccination with the first dose of MMR (MMR1) is 
recommended at 12 to 15 months of age, and the second dose 
at four to five years. Mumps vaccination was first included in the 
childhood immunisation schedule in 1988, with the introduction 
of the MMR vaccine – mumps became a notifiable disease the 
same year [1]. In 1992, a second dose of MMR was recommended 2   EUROSURVEILLANCE  Vol. 13 · Issues 4–6 · Apr–Jun 2008 · www.eurosurveillance.org
Figure 1
Mumps notifications in Ireland, by month from 2004 to 2008  
(Data for April 2008 is incomplete)
Figure 2
Mumps notifications by year and year of introduction of MMR 
vaccine in Ireland
(Prior to 2004, case classifications were not assigned to mumps notifications; therefore 
the number of confirmed mumps notifications is not known).
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Figure 3
Mumps notifications in Ireland by age group, from Week 44, 2004 
to Week 16, 2008
Figure 4
Age-specific incidence rates of mumps notifications in Ireland, 
from-Week 44, 2004 to Week 16, 2008
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Figure 5
Mumps notifications in Ireland by age group, from Weeks 1 to 16, 
2008
Figure 6
Age-specific incidence rates of mumps notifications in Ireland, 
Weeks 1 to 16, 2008
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for children aged 10 to 14 years. In 1999, the age of the second 
dose was lowered to four to five years as a result of outbreaks in 
1996/1997 that predominantly affected primary school children. 
Since the national collation of quarterly MMR1 immunisation 
uptake statistics commenced in 1999, the uptake of MMR1 in 
those aged 24 months has ranged between 69 percent (Quarter 4, 
2001) and 88 percent (Quarters 3 and 4, 2007), well below the 
target uptake of 95 percent required to prevent outbreaks of these 
diseases. The national quarterly MMR1 immunisation uptake rates 
at 24 months are shown in Figure 7.
Data on uptake of the second dose of MMR vaccine are not 
currently available at a national level.
Public health strategies and control measures
At the start of the outbreak in 2004, a national outbreak control 
team was convened [2], bringing together health professionals 
from all HSE Areas, the Department of Health and Children, the 
National Virus Reference Laboratory and the Health Protection 
Surveillance Centre (HPSC). This group agreed public health 
strategies  (vaccination  and  management  of  cases  and  close 
contacts) to control the outbreak at national and local level. 
Communication messages were standardised and control measures 
were implemented locally. 
The  outbreak  predominantly  affected  third-level  colleges 
and universities, so this population was targeted for an MMR 
vaccination programme. All students and staff under 25 years 
old who had not received two doses of MMR were recommended 
vaccination. The vaccine was provided either by public health 
services, student health services or by the student’s own general 
practitioner (GP). MMR vaccine was also provided for those at 
risk in the wider community through GP practices. Public health 
messages during the outbreak urged parents to ensure that their 
children were vaccinated with two doses of MMR by six years of 
age (i.e. routine vaccination schedule). Vaccine was provided free 
of charge by the HSE areas.
To prevent ongoing transmission of mumps virus and ensure 
high levels of immunity among the college students, the mumps 
outbreak control group also recommended that all new entrants to 
third-level colleges for the academic year 2005/2006 younger than 
25 years should be fully vaccinated with two doses of MMR prior 
to commencing the academic year.
To increase awareness of the outbreak, leaflets and information 
materials were developed and disseminated locally and made 
available on the HPSC website and other HSE websites. These 
materials included information about mumps, MMR vaccination 
and the control measures recommended. 
Since then, it has also been recommended that all new entrants 
to third-level colleges younger than 25 years for the academic years 
2006/2007 and 2007/2008 should be fully vaccinated with two 
doses of MMR prior to commencing the academic year. 
The Department of Health and Children has developed a strategy 
to expedite the elimination of measles and rubella – this is available 
on both the HPSC and EUVACNET web sites. 
The HPSC participated in the European Sero-Epidemiology 
Network 2 (ESEN2) project, funded by the European Union. This 
project provided the sero–epidemiological profile of immunity to 
eight vaccine-preventable diseases. The profile demonstrated that 
immunity against measles, mumps and rubella in primary and 
secondary school students did not reach World Health Organization 
targets. The recent resurgence in mumps cases in this age group, 
already identified as being at risk, highlights the importance of 
seroepidemiology in guiding vaccination policy, including the need 
for catch-up campaigns. The HSE is currently planning an MMR 
catch-up campaign for all schoolchildren aged between four  to 18 
years over the next two years as part of the measles elimination 
strategy. It is anticipated that this programme will also prevent 
future mumps outbreaks occurring in this age group.  This outbreak 
once again highlights the importance of a two-dose MMR schedule 
for all children.
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Figure 7
National quarterly MMR1 immunisation uptake rates at 24 months 
in Ireland
(The Q4-2005 MMR1 figure is based on data from seven of the eight HSE Areas. The 
Q1-2006 MMR1 figure includes the HSE Eastern Area figure, which is an estimate only.)
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